Status:
COMPLETED
BLAZE-Limiting Approach in NMOSD
Lead Sponsor:
Huashan Hospital
Conditions:
Neuromyelitis Optica Spectrum Disorders (NMOSD)
Eligibility:
All Genders
18+ years
Brief Summary
This is an observational cohort study based on data from the hospital-based NMOSD registry (Chinese Medical Research Registration Number MR-31-22-008563; ChiCTR2000030651). Between October 2023 (when ...
Eligibility Criteria
Inclusion
- (1)Patients have been diagnosed with NMOSD and tested seropositive for AQP4 antibody; (2) Age ≥ 18 years; (3) Received eculizumab during an acute phase of NMOSD, defined as within 30 days of attack onset； (4) Adherence to an 8-week follow-up from eculizumab initiation.
Exclusion
- Patients with unresolved Neisseria meningitidis infection or severe infections that preclude the use of immunotherapy;
- Patients with severe comorbidities (such as heart failure, respiratory failure, severe hepatic or renal dysfunction, etc.);
- Patients with incomplete records of clinical symptoms and signs, as well as insufficient data on serum marker tests in their medical records.
Key Trial Info
Start Date :
October 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 3 2025
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT06888622
Start Date
October 1 2023
End Date
March 3 2025
Last Update
March 21 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Huashan Hospital
Shanghai, Shanghai Municipality, China, 200040